Видео ютуба по тегу Nct03288545

Enfortumab vedotin in urothelial cancer
Enfortumab vedotin in urothelial cancer
EV-103: neoadjuvant enfortumab vedotin in cis-ineligible MIBC
EV-103: neoadjuvant enfortumab vedotin in cis-ineligible MIBC
EV-103 Cohort K: long-term outcomes of EV ± pembrolizumab in la/mUC
EV-103 Cohort K: long-term outcomes of EV ± pembrolizumab in la/mUC
The future of enfortumab vedotin in different stages bladder cancer
The future of enfortumab vedotin in different stages bladder cancer
EV-103 Cohort H: neoadjuvant enfortumab vedotin monotherapy in cisplatin-ineligible MIBC
EV-103 Cohort H: neoadjuvant enfortumab vedotin monotherapy in cisplatin-ineligible MIBC
How can we best sequence novel treatments in urothelial cancer?
How can we best sequence novel treatments in urothelial cancer?
PROs in advanced cisplatin-ineligible UC: first-line EV ± pembrolizumab
PROs in advanced cisplatin-ineligible UC: first-line EV ± pembrolizumab
EV-103: EV with pembrolizumab in cisplatin-ineligible urothelial carcinoma
EV-103: EV with pembrolizumab in cisplatin-ineligible urothelial carcinoma
How effective are ADCs in treating metastatic urothelial cancer?
How effective are ADCs in treating metastatic urothelial cancer?
EV-103 Cohort K: enfortumab vedotin +/- pembro in untreated cis-ineligible patients with mUC
EV-103 Cohort K: enfortumab vedotin +/- pembro in untreated cis-ineligible patients with mUC
Initial EV-103 results: enfortumab vedotin plus pembrolizumab for urothelial carcinoma
Initial EV-103 results: enfortumab vedotin plus pembrolizumab for urothelial carcinoma
Key trials in bladder cancer from ASCO GU 2022
Key trials in bladder cancer from ASCO GU 2022
Highlights in bladder cancer at ESMO 2022
Highlights in bladder cancer at ESMO 2022
Prof. Siefker-Radtke on the EV-103 trial in bladder cancer
Prof. Siefker-Radtke on the EV-103 trial in bladder cancer
EV-103: EV + pembrolizumab as a promising first-line option for urothelial carcinoma
EV-103: EV + pembrolizumab as a promising first-line option for urothelial carcinoma
What are the latest in ADCs for prostate and bladder cancer?
What are the latest in ADCs for prostate and bladder cancer?
5-year follow-up of EV and pembrolizumab for la/mUC in the EV-103 trial
5-year follow-up of EV and pembrolizumab for la/mUC in the EV-103 trial
EV-103: enfortumab vedotin and pembrolizumab in urothelial carcinoma
EV-103: enfortumab vedotin and pembrolizumab in urothelial carcinoma
Highlights from ASCO GU 2022
Highlights from ASCO GU 2022